Latest Regulatory News

SSH Mining Australia has entered a profit share mining agreement with High-Tech Metals to advance the Wagtail Gold Deposit, marking a pivotal step in the Mt Fisher Gold Project's development.

Island Pharmaceuticals has formally requested a Type C meeting with the US FDA to discuss accelerating approval of its antiviral Galidesivir for Marburg virus using the Animal Rule pathway.

Buru Energy has successfully raised $2.1 million through a share placement and launched a $3 million Share Purchase Plan to advance its Rafael Gas Project, targeting a Final Investment Decision by late 2026 and first cash flow by early 2028.

InFocus Group Holdings launches a new division focused on digital assets, AI, and big data, supported by a conditional $10 million financing from Mythos Group. The move aims to accelerate innovation in gamification and blockchain ventures.

Evolution Energy Minerals Limited’s EV1O securities have been suspended from ASX quotation due to non-compliance with a key listing rule, raising questions about the company’s regulatory standing.

Osteopore Limited has established OsteoRx, a new special purpose vehicle, with an initial AUD 0.5 million investment to accelerate breakthroughs in cellular regenerative medicine. This strategic move integrates a controlling stake in US-based RxCell Inc, expanding Osteopore’s footprint in the fast-growing stem cell market.

Finder Energy is fast-tracking development of the Kuda Tasi and Jahal oil fields in Timor-Leste, targeting initial production rates of up to 40,000 barrels per day and 10 million barrels in the first 18 months. A strategic alliance with SLB is key to accelerating engineering and reducing project risks.

Cyclone Metals has launched a comprehensive Pre-Feasibility Study for its Iron Bear iron ore project in Canada, aiming to refine development plans and attract global steel market demand.

MAC Copper Limited shareholders have decisively approved the proposed acquisition by Harmony Gold, clearing a major hurdle for the transaction. The scheme now awaits final court sanction before becoming effective.

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.

PT Aneka Tambang Tbk (ANTAM) reported a remarkable 240% surge in net profit for the half year ended June 30, 2025, driven by robust gold and nickel sales amid a challenging mining sector.

Botanix Pharmaceuticals posted a sharp revenue increase driven by its new hyperhidrosis treatment Sofdra, yet reported a substantial net loss reflecting heavy investment in commercialisation. The company’s strong cash position underpins its path to profitability.